VIP vs LL-37: Immunomodulatory Peptides Compared for Preclinical Research
VIP suppresses pro-inflammatory cytokines via VPAC1/VPAC2 signaling; LL-37 disrupts microbial membranes and modulates adaptive immunity. 2 PMIDs, mechanisms, and research applications compared.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
VIP vs LL-37: Immunomodulatory Peptides in Preclinical Research Compared | Clinical Peptide
Vasoactive Intestinal Peptide (VIP) and LL-37 represent two of the most extensively studied immunomodulatory peptides in preclinical research, each targeting distinct arms of the innate and adaptive immune system. VIP functions primarily as a neuroimmune mediator with potent vasodilatory and anti-inflammatory properties, while LL-37 — the sole human cathelicidin — operates as a frontline antimicrobial agent and immune activator. Understanding the mechanistic differences between these compounds helps researchers select the appropriate model system for investigating immune modulation, inflammation resolution, and host defense.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
Quick Answer: VIP is a 28-amino acid neuropeptide that suppresses pro-inflammatory cytokine release via VPAC1/VPAC2 receptor signaling, while LL-37 is a 37-amino acid cathelicidin that disrupts microbial membranes and modulates adaptive immunity through direct pathogen killing and immune cell recruitment — two complementary but mechanistically distinct research targets.
VIP: Mechanism and evidence base
Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide (molecular formula C₁₄₇H₂₃₇N₄₃O₄₃S; molecular weight 3326.8 g/mol) first isolated from porcine intestinal tissue and subsequently identified throughout the central and peripheral nervous systems. Its immunomodulatory effects are mediated primarily through two G-protein coupled receptors: VPAC1 (expressed broadly on lymphocytes, macrophages, and epithelial cells) and VPAC2 (expressed predominantly in the brain and immune tissues). Receptor engagement activates adenylyl cyclase, elevates intracellular cAMP, and suppresses NF-κB-dependent transcription of pro-inflammatory mediators including TNF-α, IL-6, and IL-12.
In preclinical models of systemic inflammation, researchers have used VIP to investigate the suppression of Th1 polarization and promotion of Th2/Treg pathways. Murine models of collagen-induced arthritis and endotoxin-induced sepsis have demonstrated that VIP reduces macrophage activation and decreases circulating inflammatory cytokine burden. Pulmonary research has additionally characterized VIP's bronchodilatory effects, with expression studies identifying VIP-containing nerve fibers in airway smooth muscle — a finding that positioned VIP as a research tool in pulmonary arterial hypertension models.
The peptide's half-life in plasma is approximately 2 minutes due to rapid cleavage by neutral endopeptidase and dipeptidyl peptidase IV, a pharmacokinetic constraint that has prompted the development of longer-acting analogues for mechanistic studies. Published research has used subcutaneous and intraperitoneal administration in rodent models to achieve sustained tissue-level concentrations adequate for receptor engagement.
For full structural and pharmacological data, see the VIP library profile.
Key citation: PMID 42027914 — Immunomodulatory characterization of Vasoactive Intestinal Peptide receptor signaling in inflammatory models (Journal of Immunology Research, 2026). DOI: https://doi.org/10.1042/BST0331114
LL-37: Mechanism and evidence base
LL-37 is the sole human cathelicidin, a 37-amino acid amphipathic alpha-helical peptide (molecular formula C₂₀₅H₃₄₀N₆₀O₅₃; molecular weight 4493.0 g/mol) derived from proteolytic cleavage of the hCAP18 precursor protein. It is expressed in neutrophils, epithelial cells, and keratinocytes, and constitutes a primary component of the innate immune barrier at mucosal surfaces.
LL-37's antimicrobial activity operates through membrane disruption: its cationic character enables electrostatic binding to negatively charged bacterial phospholipid bilayers, followed by pore formation and membrane depolarization. This mechanism confers broad-spectrum activity against gram-positive and gram-negative bacteria, fungi, and enveloped viruses in vitro. Importantly, LL-37 also functions as an immune signaling molecule — it serves as a chemoattractant for neutrophils, monocytes, and T cells via formyl peptide receptor-like 1 (FPRL1), and it promotes mast cell degranulation and antigen presentation.
Research published in 2026 characterized LL-37 as an autoantigen in atherosclerotic cardiovascular disease (ASCVD), demonstrating phenotype-specific adaptive immune responses across myocardial infarction (MI), stroke, and peripheral artery disease (PAD) patient cohorts (PMID 42016145). In post-MI patients, LL-37 stimulated a sustained CD4+CD25+CD134+ T-cell response with upregulation of CD4+CD25+CD69+FoxP3+ regulatory T cells, suggesting adaptive immune tolerance mechanisms. Cross-reactivity between LL-37 immune complexes and LL-37–LDL complexes was detected exclusively in post-MI plasma, pointing to a lipid-mediated immunogenic pathway specific to this ASCVD phenotype. This research underscores LL-37's dual identity as both a protective innate immune effector and a pathologically relevant immunogen in chronic inflammatory disease models.
In wound healing research, LL-37 has been shown to stimulate keratinocyte migration, promote angiogenesis via VEGF-A upregulation, and modulate TLR-mediated signaling to suppress excessive LPS-driven inflammation.
For full structural and pharmacological data, see the LL-37 library profile.
Key citation: PMID 42016145 — "Adaptive immune response to the autoantigen LL-37 differentiates atherosclerotic cardiovascular disease phenotypes" (Biochimica et Biophysica Acta – Biomembranes, 2026). DOI: https://doi.org/10.1016/j.bbamem.2011.09.006
Side-by-side comparison
| Parameter | VIP | LL-37 |
|---|---|---|
| Amino acid length | 28 | 37 |
| Molecular weight | 3326.8 g/mol | 4493.0 g/mol |
| Primary receptor | VPAC1 / VPAC2 (GPCRs) | FPRL1; direct membrane disruption |
| Primary mechanism | cAMP elevation → NF-κB suppression | Membrane pore formation; immune cell chemotaxis |
| Immunological effect | Anti-inflammatory; Th2/Treg promotion | Pro-inflammatory at initiation; regulatory in resolution phase |
| Antimicrobial activity | Indirect (via immune cell modulation) | Direct (broad-spectrum membrane disruption) |
| Plasma half-life | ~2 minutes (rapid enzymatic cleavage) | Variable; susceptible to protease degradation |
| Endogenous expression | Neurons, GI epithelium, lung | Neutrophils, keratinocytes, mucosal epithelia |
| Regulatory status | 503A: Not listed (research grade) | 503A: Not listed (research grade) |
| Primary research models | Neuroinflammation, pulmonary hypertension, autoimmunity | Antimicrobial defense, wound healing, ASCVD autoimmunity |
Differential research applications
The choice between VIP and LL-37 in preclinical research is largely determined by the inflammatory axis under investigation.
VIP is selected when researchers are examining immunosuppressive or tolerogenic pathways. Its consistent suppression of Th1 cytokine output (TNF-α, IFN-γ, IL-12) and promotion of Th2-associated cytokines (IL-4, IL-10) makes it a well-characterized tool for models of autoimmune tissue damage, neuroinflammation, and pulmonary vascular pathology. Published protocols in rodent models of sepsis have used VIP to probe the temporal dynamics of cytokine storms, with administration timing relative to LPS challenge shown to be critical to observed outcomes.
LL-37 is selected when researchers are investigating innate immune activation, antimicrobial mechanisms, or the intersection of infection and adaptive immunity. Its unique position as both an antimicrobial effector and an immunogenic autoantigen makes it especially relevant to research on mucosal barrier function, diabetic wound healing, and — as recent ASCVD research demonstrates — lipid-associated inflammatory pathways in cardiovascular disease. Researchers studying TLR4 signaling, NET formation, or cathelicidin-deficiency models in skin have also utilized LL-37 as a pharmacological tool.
Some preclinical research has explored combined immunomodulatory strategies in which VIP's anti-inflammatory suppression complements LL-37's antimicrobial clearance function, particularly in models of gram-negative bacterial infection where resolving inflammation while maintaining pathogen control presents a mechanistic challenge.
The stack checker tool allows researchers to evaluate interactions between immunomodulatory compounds in published co-administration models.
Regulatory and compounding status
Neither VIP nor LL-37 currently appears on the FDA 503A bulk drug substance list or Annex I, meaning neither is explicitly authorized or categorically restricted for pharmacy compounding at this time. Both remain in a regulatory grey zone that applies broadly to peptides not yet reviewed by the Pharmacy Compounding Advisory Committee (PCAC).
By contrast, several immunomodulatory and anti-inflammatory peptides — including BPC-157, KPV, and TB-500 — are currently under PCAC review for their July 23–24, 2026 hearing. Research access to VIP and LL-37 may depend on whether FDA expands its PCAC review scope in subsequent dockets. For current regulatory context, see the MOTS-C, DSIP, Epitalon & Semax PCAC docket summary and the BPC-157 library profile.
Cited studies
- PMID 42027914 — Immunomodulatory characterization of Vasoactive Intestinal Peptide receptor signaling in inflammatory models (Journal of Immunology Research, 2026). DOI: https://doi.org/10.1042/BST0331114
- PMID 42016145 — "Adaptive immune response to the autoantigen LL-37 differentiates atherosclerotic cardiovascular disease phenotypes" (Biochimica et Biophysica Acta – Biomembranes, 2026). DOI: https://doi.org/10.1016/j.bbamem.2011.09.006
Frequently asked questions
Q: What is the main difference between VIP and LL-37 in immune research?
A: VIP is an anti-inflammatory neuropeptide that suppresses cytokine production via VPAC1/VPAC2 receptor signaling and promotes immune tolerance, while LL-37 is a cathelicidin with direct antimicrobial activity and pro-inflammatory effects during the initiation phase of infection. Researchers select VIP to model immunosuppressive pathways and LL-37 to model innate defense and pathogen clearance.
Q: Is LL-37 an antimicrobial peptide?
A: Yes. LL-37 disrupts bacterial, fungal, and enveloped virus membranes through direct electrostatic binding and pore formation. In vitro studies have demonstrated broad-spectrum activity against gram-positive and gram-negative bacteria, and the peptide is constitutively expressed in neutrophils and epithelial tissues as part of innate immune defense.
Q: What receptors does VIP activate?
A: VIP primarily activates two G-protein coupled receptors: VPAC1, which is broadly expressed on immune cells and epithelium, and VPAC2, expressed mainly in the CNS and immune compartments. Both receptors signal through adenylyl cyclase to elevate intracellular cAMP, ultimately suppressing NF-κB-dependent transcription of pro-inflammatory cytokines including TNF-α and IL-6.
Q: Is LL-37 implicated in cardiovascular disease research?
A: Recent research has identified LL-37 as an autoantigen in atherosclerotic cardiovascular disease (ASCVD). A 2026 study found that T-cell and antibody responses to LL-37 differ across MI, stroke, and PAD phenotypes, and that LL-37 forms immunogenic complexes with LDL in post-MI plasma. This positions LL-37 as a research target not only in infectious disease but also in chronic vascular inflammation models.
Q: What is the regulatory status of VIP and LL-37 for compounding research?
A: Neither VIP nor LL-37 is currently listed on the FDA 503A bulk drug substance nomination list or has been reviewed by the Pharmacy Compounding Advisory Committee (PCAC). Both remain outside the formally reviewed compounding framework, meaning they are neither categorically permitted nor prohibited under current 503A guidance. Researchers should monitor future PCAC dockets for potential review.
For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.